Precision Medicine: A New Era for Ovarian Cancer

September 6, 2017 4:46 pm

By: Laura L. Holman, MD, MS

We’ve come a long way in treating ovarian cancer. This treatment has historically consisted of debulking surgery for nearly every patient, but it is evolving to become more informed and precise. Diagnostic laparoscopy, for … Read more

A Peek Into Big Data and Ovarian Cancer

July 31, 2017 7:33 pm

By: Annette McElhiney

On July 29, 2017, I celebrated 9 years since my IIIC ovarian cancer debulking surgery.  Because I’ve been so fortunate to be in remission, I spend hours each day researching, writing, and corresponding with other ovarian cancer … Read more

Roadblocks to Advancing Treatment of Rare Ovarian Cancers

July 26, 2017 4:37 pm

It is difficult for advances to be made in rare cancers because there are fewer patients. This makes it more challenging to conduct clinical trials for these diseases. Rare ovarian cancers are no exception to this.

In an interview with … Read more

PARP Inhibitors Changing the Landscape of Ovarian Cancer Treatment

July 11, 2017 5:53 pm

With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more

CT Technology Shows How Blood Flow Can Predict Ovarian Cancer Treatment

July 7, 2017 4:59 pm

Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer. A multi-centre clinical trial has demonstrated that CT Perfusion, which measures blood … Read more

Avastin Gains Expanded FDA Approval for Platinum-Sensitive Ovarian Cancer

December 8, 2016 7:04 pm

Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.

The approval … Read more

Profile-Matched Patient Assistance and Clinical Trial Options

May 2, 2016 8:38 pm

Clearity has taken steps to help accelerate molecular matching by enabling women to access the drugs their physicians prescribe to treat their ovarian cancer. The pilot Clearity Match Patient Assistance program that was recently announced helps subsidize the cost of … Read more

Molecular Profiling of Epithelial Ovarian Cancer

October 24, 2015 11:00 am

Epithelial ovarian cancer (EOC) is the most common cause of gynecological cancer death in the United States, with an estimated 21,290 new cases and 14,180 deaths estimated for 2015 (ACS 2015). The vast majority of women are diagnosed with advanced … Read more

Heart Drug Linked to Extra Years for Cancer Patients

October 20, 2015 11:00 am

A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.

Researchers analyzing a database … Read more